Mutational analysis of Fas ligand gene in human non-Hodgkin lymphoma

APMIS

Volumn 111, Issue 4, 2003, Pages 490-491

  Kim, Hong Sug ^a   Lee, Sug Hyung ^a   Lee, Jong Woo ^a   Soung, Young Hwa ^a   Lee, Jong Heun ^a   Park, Jik Young ^a   Cho, Yong Gu ^a   Kim, Chang Jae ^a   Kim, Su Young ^a   Lee, Yun Sil ^b   Park, Won Sang ^a   Kim, Sang Ho ^a   Lee, Jung Young ^a   Yoo, Nam Jin ^a  

^a The Catholic University of Korea   (South Korea)

^b Korea Cancer Center Hospital   (South Korea)

Author keywords

Apoptosis; Fas ligand; Mutation; Non Hodgkin lymphoma

Indexed keywords

ANTIBODY; FAS LIGAND;

APOPTOSIS; ARTICLE; CANCER; CELL DEATH; CONTROLLED STUDY; CYTOPLASM; GENE MUTATION; GENETIC CODE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NONHODGKIN LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TARGET CELL; WILD TYPE;

EID: 0038717024     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0463.2003.1110407.x     Document Type: Article

References (23)

1. Nagata S. Apoptosis by death factor. Cell 1997;88:355-65.
2. Reed JC. Mechanisms of apoptosis. Am J Pathol 2000;57:1415-30.
3. Leithäuser F, Dhein J, Mechtersheimer G, Koretz K, Bründerlein S, Henne C, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis receptor superfamily, in normal and neoplastic cells. Lab Invest 1993;69:415-29.
4. Kumar S. Mechanisms mediating caspase activation in cell death. Cell Death Differ 1999;6:1060-6.
5. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356:314-7.
6. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995;16:39-43.
7. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995;81:935-46.
8. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IAG, Debatin KM, Fischer A, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995;268:1347-9.
9. Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996;98:1107-13.
10. Beltinger C, Kurz E, Bohler T, Schrappe M, Ludwig WD, Debatin KM. CD 95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. Blood 1998;91:3943-51.
11. Tamiya S, Etoh KI, Suzushima H, Takatsuki K, Matsuoka M. Mutation of CD 95 (Fas/APO-1) gene in adult T-cell leukemia cells. Blood 1998; 91:3935-42.
12. Grønbæk K, Straten PT, Ralfkiaer E, Ahrenkiel V, Andersen MK, Hansen NE, et al. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 1998;92:3018-24.
13. Mitelman F, Mertens F, Johansson B. A break-point map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet 1997;15:417-74.
14. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
15. Lee JY, Dong SM, Kim SY, Yoo NJ, Lee SH, Park WS. A simple, precise, and economical microdissection technique for analysis of genomic DNA from archival tissue sections. Virchows Arch 1998;433:305-9.
16. Lee SH, Shin MS, Park WS, Kim SY, Kim HS, Han JY, et al. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene 1999;18:3754-60.
17. Plumas J, Jacob MC, Chaperot L, Molens JP, Sotto J J, Bensa JC. Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis. Blood 1998;91:2875-85.
18. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388:190-5.
19. Shin MS, Park WS, Kim SY, Kim HS, Kang SJ, Song KY, et al. Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma. Am J Pathol 1999;154:1785-91.
20. Nambu Y, Hughes SJ, Rehemtula A, Hamstra D, Orringer MB, Beer DG. Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. J Clin Invest 1998;101:1102-10.
21. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-78.
22. Hane M, Lowin B, Peitsch M, Becker K, Tschopp J. Interaction of peptides derived from the Fas ligand with the Fyn-SH3 domain. Interaction of peptides derived from the Fas ligand with the Fyn-SH3 domain. FEBS Lett 1995; 373:265-8.
23. Blott EJ, Bossi G, Clark R, Zvelebil M, Griffiths GM. Fas ligand is targeted to secretory lysosomes via a prolme-rich domain in its cytoplasmic tail. J Cell Sci 2001;114:2405-16.